Inform Genomics and TD2 Announce Strategic Collaboration
News Jun 26, 2014
Inform Genomics, Inc. and Translational Drug Development LLC (TD2) have announced a strategic collaboration leveraging Inform Genomics’ proprietary technology platform and analytic capabilities to biopharmaceutical companies through TD2’s oncology drug development services.
"We are very pleased to establish this strategic collaboration with TD2, as we see significant synergies between Inform Genomics’ proprietary technology and analytics along with TD2’s world-class oncology drug development service,” said Ed Rubenstein, MD, President and CEO of Inform Genomics.
Rubenstein continued, “Developing predictive genomic-based networks of side effects of early product candidates may help identify subpopulations at risk during later stages of clinical trials.”
"TD2's focus on precision oncology solutions, coupled with Inform Genomics ability to understand individual patient risk for side effects, can give a more complete vision of personalized medicine that has the opportunity to significantly improve patient care,” said Stephen Gately, PhD, President and CEO of TD2.
“Having a technology to determine who will or will not develop specific types of toxicities with a particular therapy or a new agent presents a much needed new aspect of personalized medicine,” said Daniel D. Von Hoff, MD, FACP, and Chief Development Officer of TD2.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.